OBJECTIVE: Epigenetic changes are stable and long-lasting chromatin modifications that regulate genomewide and local gene activity. The addition of two methyl groups to the 9th lysine of histone 3 (H3K9me2) by histone methyltransferases (HMT) leads to a restrictive chromatin state, and thus reduced levels of gene transcription. Given the numerous reports of transcriptional down-regulation of candidate genes in schizophrenia, we tested the hypothesis that this illness can be characterized by a restrictive epigenome. METHODS: We obtained parietal cortical samples from the Stanley Foundation Neuropathology Consortium and lymphocyte samples from the University of Illinois at Chicago (UIC). In both tissues we measured mRNA expression of HMTs GLP, SETDB1 and G9a via real-time RT-PCR and H3K9me2 levels via western blot. Clinical rating scales were obtained from the UIC cohort. RESULTS: A diagnosis of schizophrenia is a significant predictor for increased GLP, SETDB1 mRNA expression and H3K9me2 levels in both postmortem brain and lymphocyte samples. G9a mRNA is significantly increased in the UIC lymphocyte samples as well. Increased HMT mRNA expression is associated with worsening of specific symptoms, longer durations of illness and a family history of schizophrenia. CONCLUSIONS: These data support the hypothesis of a restrictive epigenome in schizophrenia, and may associate with symptoms that are notoriously treatment resistant. The histone methyltransferases measured here are potential future therapeutic targets for small molecule pharmacology, and better patient prognosis. Published by Elsevier B.V.
OBJECTIVE: Epigenetic changes are stable and long-lasting chromatin modifications that regulate genomewide and local gene activity. The addition of two methyl groups to the 9th lysine of histone 3 (H3K9me2) by histone methyltransferases (HMT) leads to a restrictive chromatin state, and thus reduced levels of gene transcription. Given the numerous reports of transcriptional down-regulation of candidate genes in schizophrenia, we tested the hypothesis that this illness can be characterized by a restrictive epigenome. METHODS: We obtained parietal cortical samples from the Stanley Foundation Neuropathology Consortium and lymphocyte samples from the University of Illinois at Chicago (UIC). In both tissues we measured mRNA expression of HMTs GLP, SETDB1 and G9a via real-time RT-PCR and H3K9me2 levels via western blot. Clinical rating scales were obtained from the UIC cohort. RESULTS: A diagnosis of schizophrenia is a significant predictor for increased GLP, SETDB1 mRNA expression and H3K9me2 levels in both postmortem brain and lymphocyte samples. G9a mRNA is significantly increased in the UIC lymphocyte samples as well. Increased HMT mRNA expression is associated with worsening of specific symptoms, longer durations of illness and a family history of schizophrenia. CONCLUSIONS: These data support the hypothesis of a restrictive epigenome in schizophrenia, and may associate with symptoms that are notoriously treatment resistant. The histone methyltransferases measured here are potential future therapeutic targets for small molecule pharmacology, and better patient prognosis. Published by Elsevier B.V.
Authors: Jonathan H Fox; David S Barber; Bhupinder Singh; Birgit Zucker; Mary K Swindell; Fran Norflus; Rodica Buzescu; Raman Chopra; Robert J Ferrante; Aleksey Kazantsev; Steven M Hersch Journal: J Neurochem Date: 2004-10 Impact factor: 5.372
Authors: Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman Journal: Genome Biol Date: 2002-06-18 Impact factor: 13.583
Authors: Kayla A Chase; Cherise Rosen; Leah H Rubin; Benjamin Feiner; Anjuli S Bodapati; Hannah Gin; Edward Hu; Rajiv P Sharma Journal: J Psychiatr Res Date: 2015-04-18 Impact factor: 4.791
Authors: P Falkai; M J Rossner; T G Schulze; A Hasan; M M Brzózka; B Malchow; W G Honer; A Schmitt Journal: Mol Psychiatry Date: 2015-03-31 Impact factor: 15.992
Authors: Kayla A Chase; Cherise Rosen; Hannah Gin; Olivia Bjorkquist; Benjamin Feiner; Robert Marvin; Sean Conrin; Rajiv P Sharma Journal: Psychiatry Res Date: 2014-11-13 Impact factor: 3.222